Economic Implications of Potential Changes to Regulatory and Reimbursement Policies for Medical Devices
To evaluate the impact of regulatory scenarios on the financial viability of medical device companies.
We developed a model to calculate the expected net present value of a hypothetical product throughout preclinical development, clinical testing, regulatory approval, and postmarketing. We tested 3 scenarios: (1) the current regulatory environment; (2) a scenario in which medical devices are subject to the same evidence standards required for pharmaceuticals; and (3) a scenario consistent with the Coverage with Evidence Development: Coverage with Study Participation (CSP) policy proposed by the Centers for Medicare and Medicaid Services, whereby Medicare will pay for beneficiaries to receive new devices that are not currently determined to be “reasonable and necessary” if the patients participate in clinical studies or registries.
Measurements and Main results
When applying assumptions consistent with the implantable cardioverter-defibrillator market, the net present value at the start of development was an estimated $553 million in the current regulatory environment, $322 million in the pharmaceutical scenario, and $403 million in the CSP scenario. Sensitivity analyses showed that the device industry would likely be profitable in all 3 scenarios over a range of assumptions.
The environment in which the medical device industry operates is financially attractive. Furthermore, when compared with the alternative of applying the same evidence standards for pharmaceuticals to medical devices, the CSP policy offers improved financial incentives for medical device companies.
- Social Security Act, Pub L 74-271, section 1862(a)(1)(A).
- Foote SB. Why Medicare cannot promulgate a national coverage rule: a case of regula mortis. J Health Polit Policy Law. 2002;27:707–30. CrossRef
- Tunis SR, Stryer DB, Clancy CM. Practical clinical trials: increasing the value of clinical research for decision making in clinical and health policy. JAMA. 2003;290:1624–32. CrossRef
- Food and Drug Administration. Device Advice: Premarket Approval. November 2002. Available at: http://www.fda.gov/cdrh/devadvice/pma/. Accessed October 23, 2006.
- Food and Drug Administration. Final Report of the Committee for Clinical Review: Based on a Review of Selected Medical Device Applications. The Temple Report. T93-12. Washington, DC: Food and Drug Administration; March 1993.
- Kessler L, Ramsey SD, Tunis S, Sullivan SD. Clinical use of medical devices in the “Bermuda Triangle.” Health Aff (Millwood). 2004;23:200–7. CrossRef
- Maisel WH. Medical device regulation: an introduction for the practicing physician. Ann Intern Med. 2004;140:296–302.
- Pilot LR, Waldmann DR. Food and Drug Administration Modernization Act of 1997: medical device provisions. Food Drug Law J. 1998;53:267–95.
- Werner C. Analyst reports medical device market flourishes. Healthc Purch News. 2003;27:30–1.
- Centers for Medicare and Medicaid Services. National coverage determinations with data collection as a condition of coverage: coverage with evidence development; July 12, 2006. Available at: https://www.cms.hhs.gov/mcd/ncpc_view_document.asp?id=8. Accessed October 23, 2006.
- Kolata G. Medicare Covering New Treatments, but with a Catch. New York Times, 5 November 2004.
- Centers for Medicare and Medicaid Services. Proposed Decision Memo For Positron Emission Tomography (FDG) for Brain, Cervical, Ovarian, Pancreatic, Small Cell Lung, and Testicular Cancers (CAG-00181N), 1 November 2004. Available at: http://www.cms.hhs.gov/mcd/viewdraftdecisionmemo.asp?id=92. Accessed October 23, 2006.
- Centers for Medicare and Medicaid Services. Proposed Decision Memo For Anticancer Chemotherapy For Colorectal Cancer (CAG-00179N), 1 November 2004. Available at: http://www.cms.hhs.gov/mcd/viewdraftdecisionmemo.asp?id=90. Accessed October 23, 2006.
- Centers for Medicare and Medicaid Services. Procedures for Making Coverage Decisions. 64 Federal Register 22619-22625 (27 April 1999).
- Stickney CP, Weil RL. Financial Accounting: An Introduction to Concepts, Methods, and Uses, 10th ed. Cincinnati, Ohio: South-Western College Publishing; 2003.
- DiMasi JA, Hansen RW, Grabowski HG. The price of innovation: new estimates of drug development costs. J Health Econ. 2003;22:151–85. CrossRef
- Center for Drug Evaluation and Research, Food and Drug Administration. FDA’s Drug Review and Approval Times. Available at: http://www.fda.gov/cder/reports/reviewtimes/default.htm. Accessed October 23, 2006.
- Centers for Medicare and Medicaid Services. Review of National Coverage Determinations and Local Coverage Determinations; Final Rule. 68 Federal Register 63692-63731 (7 November 2003).
- International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH). The extent of population exposure to assess clinical safety. ICH-E1A. Available at: http://www.fda.gov/cder/guidance/iche1a.pdf. Accessed October 23, 2006.
- Eisenstein EL, Lemons PW 2nd, Tardiff BE, Schulman KA, Jolly MK, Califf RM. Reducing the costs of phase III cardiovascular clinical trials. Am Heart J. 2005;149:482–8. CrossRef
- Heart disease and stroke statistics—2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2006;113:e85–151. Erratum in: Circulation. 2005;113:e696.
- Hlatky MA, Mark DB. The high cost of implantable defibrillators. Eur Heart J. 2006;( doi: 10.1093/eurheartj/ehl311).
- Guidant Annual Report 2003. Indianapolis: Guidant Corporation; 2003. Available at: http://www.guidant.com/investors/annualreport/2003/Guidant_AR2003.pdf. Accessed November 18, 2005.
- Economic Implications of Potential Changes to Regulatory and Reimbursement Policies for Medical Devices
- Open Access
- Available under Open Access This content is freely available online to anyone, anywhere at any time.
Journal of General Internal Medicine
Volume 23, Issue 1 Supplement, pp 50-56
- Cover Date
- Print ISSN
- Online ISSN
- Additional Links
- device approval
- health policy
- reimbursement mechanisms
- Industry Sectors
- Author Affiliations
- 1. Center for Clinical and Genetic Economics, Duke Clinical Research Institute, PO Box 17969, Durham, NC, 27715, USA
- 2. Department of Medicine, Duke University School of Medicine, Durham, NC, USA
- 3. Health Sector Management Program, The Fuqua School of Business, Duke University, Durham, NC, USA